Literature DB >> 24649025

Effects of the C-terminal of endostatin on the tumorigenic potential of H22 cells.

Xia Qi1, Yuejian Liu2, Wei Wei1, Xiaohua Huang1, Yunfei Zuo1.   

Abstract

Endostatin is an endogenous angiogenesis inhibitor whose specific functional site has not yet been determined. In the present experiment, 13 amino acids (LCIENSFMTSFSK) were selectively deleted from the C-terminal of endostatin and the resulting mutant endostatin was named EM13. To determine the effect of the C-terminal deletion on the biological activity of endostatin, EM13, wild-type endostatin and empty plasmid were transfected into H22 cells. After 48 h, the three types of transfected cells were harvested and injected into nude mice. The results demonstrated that there was no significant difference in tumor size, as determined by hematoxylin and eosin staining, between the EM13-transfected group and the endostatin and empty plasmid groups, although the nude mice that were injected with EM13-transfected H22 cells exhibited smaller tumors and lower density of blood vessels compared to those injected with endostatin- and empty plasmid-transfected H22 cells. The results suggested that the 13 amino acids of the C-terminal of endostatin do not play an important role in the tumorigenic potential of H22 cells. This experiment was unsuccessful in reproducing the results of several investigators. Therefore, the mechanism underlying the tumorigenesis of H22 cells remains to be elucidated.

Entities:  

Keywords:  H22 cells; endostatin; tumorigenesis

Year:  2013        PMID: 24649025      PMCID: PMC3917031          DOI: 10.3892/br.2013.147

Source DB:  PubMed          Journal:  Biomed Rep        ISSN: 2049-9434


  31 in total

1.  Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance.

Authors:  T Boehm; J Folkman; T Browder; M S O'Reilly
Journal:  Nature       Date:  1997-11-27       Impact factor: 49.962

2.  Cell surface glypicans are low-affinity endostatin receptors.

Authors:  S A Karumanchi; V Jha; R Ramchandran; A Karihaloo; L Tsiokas; B Chan; M Dhanabal; J I Hanai; G Venkataraman; Z Shriver; N Keiser; R Kalluri; H Zeng; D Mukhopadhyay; R L Chen; A D Lander; K Hagihara; Y Yamaguchi; R Sasisekharan; L Cantley; V P Sukhatme
Journal:  Mol Cell       Date:  2001-04       Impact factor: 17.970

3.  Endostatin blocks vascular endothelial growth factor-mediated signaling via direct interaction with KDR/Flk-1.

Authors:  Young-Mi Kim; Sewook Hwang; Young-Myoeng Kim; Bo-Jeong Pyun; Tae-Yoon Kim; Seung-Taek Lee; Yong Song Gho; Young-Guen Kwon
Journal:  J Biol Chem       Date:  2002-05-23       Impact factor: 5.157

4.  Increased concentrations of the circulating angiogenesis inhibitor endostatin in patients with systemic sclerosis.

Authors:  M Hebbar; J P Peyrat; L Hornez; P Y Hatron; E Hachulla; B Devulder
Journal:  Arthritis Rheum       Date:  2000-04

5.  Phase I study of recombinant human endostatin in patients with advanced solid tumors.

Authors:  Roy S Herbst; Kenneth R Hess; Hai T Tran; Jennifer E Tseng; Nizar A Mullani; Chusilp Charnsangavej; Timothy Madden; Darren W Davis; David J McConkey; Michael S O'Reilly; Lee M Ellis; James Pluda; Waun K Hong; James L Abbruzzese
Journal:  J Clin Oncol       Date:  2002-09-15       Impact factor: 44.544

6.  Endostatin binding to ovarian cancer cells inhibits peritoneal attachment and dissemination.

Authors:  Yumi Yokoyama; Gerald Sedgewick; S Ramakrishnan
Journal:  Cancer Res       Date:  2007-11-15       Impact factor: 12.701

7.  Endostatin gene therapy enhances the efficacy of paclitaxel to suppress breast cancers and metastases in mice.

Authors:  Jie Li; Xuesong Dong; Zongzhen Xu; Xian Jiang; Hongchi Jiang; Geoffrey W Krissansen; Xueying Sun
Journal:  J Biomed Sci       Date:  2007-08-18       Impact factor: 8.410

8.  Endostar, a novel recombinant human endostatin, exerts antiangiogenic effect via blocking VEGF-induced tyrosine phosphorylation of KDR/Flk-1 of endothelial cells.

Authors:  Yun Ling; Yong Yang; Na Lu; Qi-dong You; Sen Wang; Ying Gao; Yan Chen; Qing-Long Guo
Journal:  Biochem Biophys Res Commun       Date:  2007-07-10       Impact factor: 3.575

9.  Paneling human thyroid cancer cell lines for candidate proteins for targeted anti-angiogenic therapy.

Authors:  Sebastian Hoffmann; Anette Wunderlich; Ilhan Celik; Katja Maschuw; Iyad Hassan; Lorenz C Hofbauer; Andreas Zielke
Journal:  J Cell Biochem       Date:  2006-07-01       Impact factor: 4.429

10.  CD36 mediates the In vitro inhibitory effects of thrombospondin-1 on endothelial cells.

Authors:  D W Dawson; S F Pearce; R Zhong; R L Silverstein; W A Frazier; N P Bouck
Journal:  J Cell Biol       Date:  1997-08-11       Impact factor: 10.539

View more
  2 in total

1.  Evaluation of the diagnostic value of the immunoblotting and ELISA tests using recombinant Em18 antigen in human alveolar echinococcosis from Xingjiang China.

Authors:  Xiao-Juan Bi; Yin-Mei Shao; Liang Li; Yan Wang; Chuan-Shan Zhang; Guo-Dong Lü; Tuerganaili Aji; Jun Li; Wen-Bao Zhang; Hao Wen; Ren-Yong Lin
Journal:  Exp Ther Med       Date:  2018-08-01       Impact factor: 2.447

2.  Efficacy of pEgr-1-endostatin combined with ionizing radiation on hypoxic conditions in nude mice bearing SKOV3 ovarian carcinoma.

Authors:  Yong-Chun Zhang; Xiu-Mei Li; Zhuang Yu; Xiao-Li Shi; Yong Li; Wan-Lin Wang
Journal:  Oncol Lett       Date:  2017-01-02       Impact factor: 2.967

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.